Cullinan Therapeutics, Inc. CGEM Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $88.33M+6.4% | $83.01M-15.7% | $98.43M-37.0% | $156.15M+161% | ||
| $289.56M-8.4% | $315.97M-14.3% | $368.63M+18.5% | $311.14M+34.9% | ||
| $42.87M-25.7% | $57.67M+51.1% | $38.17M+17.1% | $32.61M+16.2% | ||
| $386.76M-6.7% | $414.67M-13.6% | $480.19M+1.2% | $474.47M+60.0% | ||
| $421K-38.4% | $683K-30.9% | $989K-15.8% | $1.17M+1,425% | ||
| $2.63M+57.8% | $1.67M-34.4% | $2.54M-38.4% | $4.13M— | ||
| $297K-18.9% | $366K-20.3% | $459K0.0% | $459K+212% | ||
| $58.27M-71.5% | $204.44M— | $0-100% | $80.88M-42.4% | ||
| $448.37M-27.9% | $621.82M+28.4% | $484.18M-13.7% | $561.12M+28.3% | ||
| $8.43M-7.0% | $9.06M+13.7% | $7.97M-41.3% | $13.58M+28.3% | ||
| $36.12M+30.6% | $27.66M+14.3% | $24.2M+71.2% | $14.14M+64.8% | ||
| $780K-40.1% | $1.3M-9.6% | $1.44M+1.3% | $1.42M+181% | ||
| $37.74M+23.1% | $30.65M+8.9% | $28.14M+25.1% | $22.5M+91.5% | ||
| $1.9M+124% | $849K-60.5% | $2.15M-40.1% | $3.59M+312% | ||
| $2.68M+24.7% | $2.15M-40.1% | $3.59M-28.4% | $5.01M— | ||
| $39.64M+25.9% | $31.5M+4.0% | $30.29M+16.1% | $26.09M+121% | ||
| $0— | $0— | $0— | $0— | ||
| $6K0.0% | $6K+50.0% | $4K-20.0% | $5K+25.0% | ||
| $995.82M+3.9% | $958.7M+46.4% | $654.69M+11.9% | $585.32M+0.1% | ||
| -$588.12M-59.7% | -$368.24M-83.3% | -$200.86M-321% | -$47.7M+70.0% | ||
| $1.02M+867% | -$133K-3.1% | -$129K+95.0% | -$2.6M-210% | ||
| $0— | $0-100% | $192K— | $0-100% | ||
| $408.73M-30.8% | $590.33M+30.1% | $453.7M-15.2% | $535.03M+25.9% | ||
| $448.37M-27.9% | $621.82M+28.4% | $484.18M-13.7% | $561.12M+28.3% | ||
| $297K-18.9% | $366K-20.3% | $459K0.0% | $459K+212% | ||
| $2.63M+57.8% | $1.67M-34.4% | $2.54M-38.4% | $4.13M— | ||
| $58.27M-71.5% | $204.44M— | $0-100% | $80.88M-42.4% | ||
| $2.63M+57.8% | $1.67M-34.4% | $2.54M-38.4% | $4.13M— | ||
| $297K-18.9% | $366K-20.3% | $459K0.0% | $459K+212% | ||
| $289.56M-8.4% | $315.97M-14.3% | $368.63M+18.5% | $311.14M+34.9% | ||
| $2.63M+57.8% | $1.67M-34.4% | $2.54M-38.4% | $4.13M— | ||
| $297K-18.9% | $366K-20.3% | $459K0.0% | $459K+212% | ||
| $36.12M+30.6% | $27.66M+14.3% | $24.2M+71.2% | $14.14M+64.8% | ||
| $36.12M+30.6% | $27.66M+14.3% | $24.2M+71.2% | $14.14M+64.8% | ||
| $2.68M+24.7% | $2.15M-40.1% | $3.59M-28.4% | $5.01M+264% | ||
| $995.82M+3.9% | $958.7M+46.4% | $654.69M+11.9% | $585.32M+0.1% | ||
| $6K0.0% | $6K+50.0% | $4K-20.0% | $5K+25.0% | ||
| $0— | $0— | $0— | $0— | ||
| $8.86M-43.5% | $15.69M+19.6% | $13.12M+82.8% | $7.18M+17.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cullinan Therapeutics, Inc.'s total assets?
- Cullinan Therapeutics, Inc. (CGEM) holds $403.0M in total assets, down 30.5% year over year.
- How much cash does Cullinan Therapeutics, Inc. have?
- Cullinan Therapeutics, Inc. holds $75.1M in cash and equivalents.
- Can Cullinan Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 10.28 — current assets exceed current liabilities.
- Where does Cullinan Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.